Jane Street’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.52M Buy
177,700
+121,800
+218% +$5.33M ﹤0.01% 2742
2025
Q4
$2.16M Buy
+55,900
New +$2.13M ﹤0.01% 4673
2025
Q3
Sell
-63,300
Closed -$2.28M 11621
2025
Q2
$2.28M Buy
63,300
+56,700
+859% +$1.88M ﹤0.01% 4216
2025
Q1
$205K Buy
+6,600
New +$209K ﹤0.01% 8408
2024
Q2
Sell
-27,200
Closed -$826K 10076
2024
Q1
$826K Sell
27,200
-5,800
-18% -$171K ﹤0.01% 5749
2023
Q4
$927K Sell
33,000
-2,700
-8% -$74.2K ﹤0.01% 5696
2023
Q3
$969K Buy
+35,700
New +$1.06M ﹤0.01% 5228
2023
Q1
Sell
-29,500
Closed -$1.17M 9790
2022
Q4
$1.17M Sell
29,500
-7,300
-20% -$305K ﹤0.01% 4745
2022
Q3
$1.48M Buy
36,800
+14,700
+67% +$628K ﹤0.01% 4707
2022
Q2
$929K Sell
22,100
-2,500
-10% -$102K ﹤0.01% 5618
2022
Q1
$958K Sell
24,600
-69,100
-74% -$2.71M ﹤0.01% 6222
2021
Q4
$3.73M Sell
93,700
-26,900
-22% -$1.05M ﹤0.01% 3321
2021
Q3
$4.36M Buy
120,600
+110,700
+1,118% +$4.3M ﹤0.01% 2968
2021
Q2
$406K Buy
9,900
+2,300
+30% +$97.8K ﹤0.01% 7635
2021
Q1
$332K Buy
+7,600
New +$360K ﹤0.01% 7530

Other funds holding RPRX

Jane Street's RPRX Position: Q1 2026 in Review

Jane Street reduced its Royalty Pharma (RPRX) stake by 51% in Q1 2026, selling an estimated $112M and leaving 2,400,382 shares worth $115M. The position accounts for 0.01% of the portfolio, ranked #580.

Jane Street first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. The position peaked at $191M in Q4 2025. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Jane Street held 2,400,382 shares of Royalty Pharma worth $115M as of Q1 2026.
  • Jane Street sold 2,547,027 Royalty Pharma shares in Q1 2026, an estimated $112M.
  • Royalty Pharma made up 0.01% of Jane Street's portfolio in Q1 2026, its #580 holding.
  • Jane Street first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • Jane Street's Royalty Pharma position peaked at $191M in Q4 2025.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.